Johnson & Johnson’s new diabetes drug linked to coma and death
A Philadelphia man is suing Johnson & Johnson, claiming the pharmaceutical giant’s diabetes drug, Invokana, damaged his kidneys. Invokana is made by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary.
The commonly-prescribed drug had only been on the market for two years before the U.S. Food and Drug Administration determined it caused “too much acid in the blood and serious urinary tract infections,” according to reports, resulting in the required placement of a warning label on its packaging last month.(1)
Enforced by the U.S. Food and Drug Administration, the new drug warning applies to an entire class of diabetes medication called SGLT2 (sodium-glucose co-transporter) inhibitors, for which Invokana is included. SGLT2 inhibitors work by preventing sugar from being reabsorbed into the bloodstream.
Series of side effects plague common diabetes drug, yet it remained on the market
On Dec. 4, 2015, the FDA forced Johnson & Johnson and other manufacturers of SGLT2 inhibitors to warn consumers via labeling that the drugs may cause ketoacidosis, a serious condition that can cause diabetic comas and death, according to the American Diabetes Association.(2)
Invokana has been linked to other complications, as well. In 2015, it was reported that Invokana could increase the risk for developing kidney problems, including “kidney failure or impairment, dehydration and fluid imbalances, kidney stones, urinary tract infections and abnormal weight loss.”
In 2013, shortly after the drug’s release, the ADA determined that Invokana increased men and women’s risk for develo Continue reading